TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Patient in an intensive care unit~* Weight greater or equal to 50 kgs~* Fever: core body temperature greater than or equal to 38.3 degrees Celsius~* Clinically stable: no active resuscitation with fluids, blood products, or dose increases of vasoactive medications within 1 hour of study drug administration~Exclusion Criteria:~* Acetaminophen hypersensitivity~* Acute liver failure or acute liver injury~* Heat stroke, malignant hyperthermia, neuroleptic malignant syndrome~* Therapeutic cooling, physical cooling, extracorporeal blood circuit therapies~* Administration of acetaminophen-containing medications, non-steroidal anti-inflammatory drugs, or aspirin greater than 81 mg within specified times per drug prior to fever presentation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal saline placebo (Type: PLACEBO_COMPARATOR): Normal saline 100 mLs intravenous, administered over 15 minutes
- Acetaminophen (Type: EXPERIMENTAL): Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: INtervention Study In overweiGHT Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 40 years or older at time of eligibility screening;~* Body mass index 25.0-44.9 kg/m2 (also see Figure 2);~* Smoked more than 10 pack-years of cigarettes;~* Shortness of breath;~* COPD;~* Able to participate fully in all study protocol/procedures including written informed consent process.~Exclusion Criteria:~* Inability to speak, read, or understand English;~* Active weight loss interventions;~* Expected weight loss because of alternate explanations, such as from illness;~* Unable to ambulate to weight scale for weight measurement;~* Safety and/or adherence concerns due to severe physical or mental health issues or life expectancy \<18 months;~* Pregnant, lactating, or planning to become pregnant during the study period;~* Participation in other intervention studies.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lifestyle intervention (Type: ACTIVE_COMPARATOR): Behavioral lifestyle intervention focused on healthy eating and physical activity
- Usual Care (Type: NO_INTERVENTION): Participants continue with usual diet and exercise activities as they desire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Stimulation Followed by a Fresh Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Poor prognosis patients according to the POSEIDON group 3 \& 4 (based on AMH)~* AMH \<1.2~* age \<40 years old~* BMI \>18 and \<35 kg/m2~* Body weight \>50kg (in women \<36 years old body weight \>60kg)~Exclusion Criteria:~* Maternal age \> 40 years~* History of untreated autoimmune, endocrine or metabolic disorders~* Previous ovarian cystectomy or oophorectomy~* Body weight \<50kg (and body weight \<60kg in women \<36 years old)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Double Stimulation (Elonva+rFSH) in luteal /follicular phase (Type: EXPERIMENTAL): A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp \& Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)
- Conventional Stimulation (Elonva+rFSH) in follicular phase (Type: ACTIVE_COMPARATOR): A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Patient Preoperative Skin Prep Persistence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of any race~* Subjects in good general health~* Minimum skin flora baseline requirements on abdomen and groin~Exclusion Criteria:~* Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test areas~* Topical antimicrobial exposure within 14 days prior to screening and treatment days~* Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 3M CHG/IPA - Abdominal Region (Type: EXPERIMENTAL): Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
- Normal Saline - Abdominal Region (Type: PLACEBO_COMPARATOR): Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
- 3M CHG/IPA - Inguinal Region (Type: EXPERIMENTAL): Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
- Normal Saline - Inguinal Region (Type: PLACEBO_COMPARATOR): Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known sarcoidosis 17~* Age 18 or greater~* Patients with documented pulmonary hypertension with a PA mean \> 25 mm as measured by cardiac catheterization within six months of entry into the study~* Patients with dyspnea~* Six minute walk distance of between 100 to 500 meters~* Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab~* Patients able to provide written consent~Exclusion Criteria:~* Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)~* Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%~* Patients with World Health Organization (WHO) class IV status~* Patients who are pregnant or breast feeding~* Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%~* Significant liver dysfunction not due to sarcoidosis~* Patients with severe other organ disease felt by investigators to impact survival during the course of the study~* Patients unable to perform the 6 inhalation treatments required for therapy~* Patients with \< 90 mm Hg Systolic systemic blood pressure will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physical status American Society of Anesthesiologist (ASA) I or II~* Electively scheduled for laparoscopic hysterectomy,~Exclusion Criteria:~* Patients who refuse to participate~* Body mass index (BMI) \> 30~* ASA physical status \> II~* Diabetes~* Major illnesses (e.g., cardiac, respiratory, renal, hepatic or neurological)~* Coagulation abnormalities~* Pregnancy~* Known hypersensitivity to aripiprazole or contraindications to its use (a psychiatric illness, patients on antidepressants, dementia-related psychosis)~* History of drug addiction or alcohol abuse~* Mental retardation interfering with the evaluation of pain scores or PCA programs .

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane Protective Effect on Ischemia-reperfusion Injury. Multicenter, Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patient selected for plastic breast surgery With microsurgical Free flap Over 18 y Asa I/II~Exclusion Criteria:~Unusual reaction to anesthetic drugs Suspect for malignant hyperthermia Vasculopathic disease Coagulation disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Total intravenous anesthesia (Type: ACTIVE_COMPARATOR): Total intravenous anaesthesia
- Balanced anesthesia (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 8-14 years~* Race: African American or Caucasian~* Children not taking multivitamins for at least 1 month before enrollment and agree not to start any multivitamin supplements during the 6-month trial period.~* Children who are on multivitamins can be considered for enrollment only if they are able to and agree to stop their multivitamin tablet for a 1 month washout period prior to enrollment.~* Absence of chronic diseases that could affect growth or calcium or vitamin D metabolism~Exclusion Criteria:~* Hepatic or renal disease~* Metabolic rickets~* Malabsorptive disorders (Crohn's disease, cystic fibrosis and celiac disease) or cancer~* Treatment with anticonvulsants or systemic glucocorticoids

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Vitamin D3 1000 IU Tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old infants.~* Available for the entire study period.~Exclusion criteria:~* Previous vaccination with any vaccine before the start of the study.~* Known contraindication to vaccination.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 13vPnC vaccine (Type: EXPERIMENTAL): None
- 7vPnC vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signature of informed consent~* At least 18 years old~* Patients on their 1st ARV treatment consisting on 2 NRTIs + 1 third agent for at least 1 year~* Undetectable viral load for at least 6 months prior to inclusion in the study (VL\<50 c/mL in 2 determinations 6 months apart; blips are not allowed).~* Requirement of ARV treatment change due to toxicity, intolerance or simplification.~* Clinically stable.~Exclusion Criteria:~* Pregnant women or women who plan to get pregnant during the study.~* Breast feeding~* History of change of any ARV treatment component for any reason 4 months prior to the inclusion in the trial~* History of ARV treatment change due to virological failure~* History of confirmed virological failure defined as one single VL \>400 c/mL or at least 2 VL between 50 and 400 c/mL one year after an indetectable VL was achieved.~* Absence of HIV genotype prior to ARV treatment initiation.~* Resistance mutation to any of the study drugs (ATV, RTV, 3TC)~* HBV infection.~* History of toxicity or intolerance to ATV, RTV or 3TC.~* Gilbert's syndrome.~* Use of contraindicated drugs.~* Lab abnormalities grade 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATV/r+3TC (Type: EXPERIMENTAL): Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
- ATV/r+2 NRTIs (Type: ACTIVE_COMPARATOR): Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Medication-based Analgesia in Humans

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-75~* Urine sample tests negative for common illicit substances of abuse, including cannabis~* Medically cleared to take study medications~* Are not pregnant or breast feeding~* Willing to comply with the study protocol.~Exclusion Criteria:~* Meet DSM-5 criteria for alcohol/substance use disorder~* Taking opioids for pain~* Previous adverse reaction to a cannabinoid product~* Prescribed and taking stimulants or benzodiazepines~* Answer yes to item 1 of the Brief Pain Inventory indicating chronic pain~* Self-report any illicit drug use in the past 7 days~* Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse event~* History of seizure disorder~* Have a known allergy to the study medications or sesame seed oil~* Taking medications contraindicated with hydromorphone or dronabinol~* Have a history of clinically significant cardiac arrhythmias or vasopastic disease~* Have an abnormal and clinically-significant ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + Placebo (Type: PLACEBO_COMPARATOR): Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg + Placebo (Type: ACTIVE_COMPARATOR): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
- Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine Analgesia For Removal Of Wound Vac Dressings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. wounds to which a split-thickness autologous skin graft applied;~2. infected wounds after debridement;~3. open fracture wounds;~4. acute soft-tissue wounds (with exposed tendon, bone, hardware, and/or joint);~5. fasciotomy wounds after compartment syndrome;~6. chronic non-healing wounds;~7. surgical wounds that are difficult to close due to tension; or~8. wounds with external fixation pins or tubes with irritation or drainage.~Exclusion Criteria:~1. allergy to lidocaine;~2. allergy to the polyurethane foam or impermeable seal;~3. malignancy associated with the wound;~4. extremity insensate to pain due to any cause (including diabetic neuropathy, or any neurologic disorder therein);~5. pregnancy as diagnosed by urine pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine then Placebo-Saline (Type: PLACEBO_COMPARATOR): None
- Placebo-Saline then Lidocaine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is a female ≥18 years old.~2. Presents with a diagnosis of Stage IIIC ovarian cancer.~3. Presents with high-grade serous carcinoma.~4. Has one of the following:~   1. Visible residual tumor ≤1 cm after primary tumor debulking surgery.~  2. Three cycles of neoadjuvant chemotherapy and complete resection after interval tumor debulking surgery.~  3. Three cycles of neoadjuvant chemotherapy and visible residual tumor ≤1 cm after interval tumor debulking surgery.~5. ECOG performance status of 0 or 1.~6. Is willing to comply with required follow-up study visits.~7. Is willing and able to provide written informed consent.~Exclusion Criteria:~1. Has a life expectancy of \<3 months.~2. Is pregnant, as confirmed through a blood test prior to any study procedure, planning on becoming pregnant during the study, or is lactating.~3. Will be receiving intraperitoneal chemotherapy.~4. Has undergone prior treatment with abdominal and/or pelvic radiotherapy.~5. Has significant active concurrent medical illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~6. Presence of central nervous system or cerebral metastases.~7. Recurrent ovarian cancer.~8. Complete resection with no residual tumor after primary tumor debulking surgery.~9. Suboptimal resection with \>1 cm residual tumor after primary or interval tumor debulking surgery.~10. Is simultaneously enrolled in another investigational study.~11. Has a history of cancer within 5 years other than in-situ uterine cervix cancer or non-melanoma skin cancer.~12. Has a known hypersensitivity to carboplatin or paclitaxel.~13. Is concurrently using other antineoplastic agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M-Trap (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete